Karuna clears PhII hurdle in schizophrenia, takes aim at a pivotal in blockbuster hunt — shares soar
When Karuna went public last year, the biotech cited one small Eli Lilly study of their anti-psychotic xanomeline that delivered a whopping 24-point average …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
